TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07697586: A Phase II Clinical Study to Evaluate Sacituzumab Tirumotecan (SKB264) in Combination With SKB118 for the Treatment of Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 206 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07697586 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07697586 Rescue Dossier →